2002
Prevention of Human Immunodeficiency Virus—Related Opportunistic Infections in France: A Cost-Effectiveness Analysis
Yazdanpanah Y, Goldie S, Paltiel A, Losina E, Coudeville L, Weinstein M, Gerard Y, Kimmel A, Zhang H, Salamon R, Mouton Y, Freedberg K. Prevention of Human Immunodeficiency Virus—Related Opportunistic Infections in France: A Cost-Effectiveness Analysis. Clinical Infectious Diseases 2002, 36: 86-96. PMID: 12491207, DOI: 10.1086/344902.Peer-Reviewed Original ResearchConceptsCost-effectiveness ratioTMP-SMZAntiretroviral therapyHIV diseaseOpportunistic infectionsHuman immunodeficiency virus (HIV) diseaseMycobacterium avium complex bacteremiaIncremental cost-effectiveness ratioPerson lifetime costsActive antiretroviral therapyEra of HAARTPneumocystis carinii pneumoniaHuman immunodeficiency virusQuality-adjusted life expectancyCost-effectiveness analysisOral ganciclovirCytomegalovirus infectionToxoplasmic encephalitisCarinii pneumoniaImmunodeficiency virusTherapeutic optionsClinical impactFrench patientsProphylaxisInfection
2001
Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts
Yazdanpanah Y, Chêne G, Losina E, Goldie S, Merchadou L, Alfandari S, Seage G, Sullivan L, Marimoutou C, Paltiel A, Salamon R, Mouton Y, Freedberg K. Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts. International Journal Of Epidemiology 2001, 30: 864-871. PMID: 11511618, DOI: 10.1093/ije/30.4.864.Peer-Reviewed Original ResearchConceptsPneumocystis carinii pneumoniaPrimary opportunistic infectionCommon opportunistic infectionOpportunistic infectionsCarinii pneumoniaToxoplasmic encephalitisCytomegalovirus infectionIncidence rateGroupe d'Epidémiologie Clinique du SIDAAIDS Reference CenterCD4 lymphocyte declineIncidence of HIVHuman immunodeficiency virusAbsence of prophylaxisHIV risk behaviorsHigh incidence rateHospital-based information systemCandida esophagitisCount declineImmunodeficiency virusLymphocyte declineAntiretroviral drugsClinical guidelinesSpecific infectionsClinical cohort